Deal Watch: Allergan, Regeneron Both Look To Hydrogel Tech
Most of the significant deal-making action during the past week took place in Asia as Piramal made a play to increase its injectables business, an Eisai affiliate out-licensed rights to ovarian cancer candidate farletuzumab, and EpimAb and Kymab agreed to collaborate on bispecific antibody therapeutics.
You may also be interested in...
The VC firm known for its new company formation efforts will launch 10-12 biopharma, device and diagnostic ventures with its fifth fund. Also, EpimAb raises a $74m series B round, three more drug developers join the IPO queue and Amicus leads recent follow-on offerings.
Regeneron is partnering with the troubled ophthalmology-focused biotech to develop a sustained-release formulation of Eylea that could enable a less-frequent dosing regimen.
Piramal is continuing on its acquisitive spree, snapping up a basket of injectable products from Janssen that are expected to give the diversified Indian group a foothold in the $20bn-plus global generic injectable hospital drugs market.